Hong Kong Stock Exchange · Healthcare
Invest in WuXi XDC Cayman stock from India
Indian and foreign residents can buy WuXi XDC Cayman (2268) shares directly through Paasa.
By Paasa · Updated
WuXi XDC Cayman at a glance
- Price
- HK$80.80+HK$2.75 (3.52%)
- Market cap
- HK$102.32B
- Day range
- HK$78.00 – HK$82.10
- P/E
- 56.55
- Dividend yield
- None
- Volume
- 2.35M
- 1 month
- +10.08%
- 6 months
- +37.18%
- YTD
- +33.00%
- 1 year
- +7.59%
- 5 years
- —
WuXi XDC Cayman statements, FY2021–FY2025
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | CN¥5.9B | CN¥4.1B | CN¥2.1B | CN¥990.4M | CN¥311.1M |
| Gross profit | CN¥2.1B | CN¥1.2B | CN¥559.6M | CN¥261.1M | CN¥113.5M |
| Operating income | CN¥1.6B | CN¥948.5M | CN¥365.5M | CN¥125.9M | CN¥60.1M |
| Net income | CN¥1.5B | CN¥1.1B | CN¥283.5M | CN¥155.7M | CN¥54.9M |
| Earnings per share | CN¥1.22 | CN¥0.89 | CN¥0.26 | CN¥0.13 | CN¥0.05 |
| EBITDA | CN¥1.8B | CN¥1.3B | CN¥420.3M | CN¥151.7M | CN¥77.4M |
| Total assets | CN¥14.4B | CN¥9.1B | CN¥6.7B | CN¥2.5B | CN¥879.8M |
| Total debt | CN¥879.5M | CN¥496.4M | CN¥2.8M | CN¥77.2M | CN¥24.6M |
| Cash and short-term investments | CN¥7.5B | CN¥4.0B | CN¥4.0B | CN¥735.0M | CN¥26.3M |
| Shareholders' equity | CN¥10.7B | CN¥6.6B | CN¥5.5B | CN¥1.5B | CN¥20.9M |
| Operating cash flow | CN¥1.8B | CN¥717.2M | CN¥332.8M | CN¥251.8M | CN¥59.1M |
| Free cash flow | CN¥634.6M | −CN¥788.0M | −CN¥206.5M | CN¥50.4M | CN¥7.2M |
| Capital expenditure | −CN¥1.2B | −CN¥1.5B | −CN¥539.4M | −CN¥201.4M | −CN¥51.9M |
Fiscal years as reported, the latest ending 31 Dec 2025. Figures in CNY; a dash means the provider reported nothing for that line.
Peer comparison
| Company | Ticker | Price | Market cap |
|---|---|---|---|
| CSPC Pharmaceutical | 1093.HK | HK$10.00 | HK$114.05B |
| Akeso | 9926.HK | HK$108.70 | HK$100.00B |
| Pharmaron Beijing | 3759.HK | HK$31.22 | HK$85.20B |
| Shanghai Fosun Pharmaceutical | 2196.HK | HK$18.27 | HK$68.44B |
| Shanghai Pharmaceuticals | 2607.HK | HK$10.94 | HK$63.46B |
| Hangzhou Tigermed Consulting | 3347.HK | HK$47.34 | HK$57.47B |
| Alibaba Health Information Technology | 0241.HK | HK$2.85 | HK$46.10B |
| Joinn Laboratories(China)Co. | 6127.HK | HK$29.80 | HK$40.80B |
Peers as grouped by the data provider. This is not an investment recommendation.
How to invest in WuXi XDC Cayman from India
Step 1
Open your Paasa account
KYC takes a few minutes: PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Step 2
Add funds from your Indian bank account
Remit up to $250,000 a year under the RBI's Liberalised Remittance Scheme. Your bank converts the rupees to US dollars at its rate on the day you remit, and Interactive Brokers converts the dollars to HKD when you buy.
Step 3
Search 2268 and buy
Find WuXi XDC Cayman by name or by its ticker, 2268, and place your order. Many Hong Kong listings trade in board lots, so the smallest order is one lot rather than one share.
Why invest in WuXi XDC Cayman from India
What WuXi XDC Cayman does
WuXi XDC Cayman Inc. operates as an investment holding company and a global contract research, development, and manufacturing organization (CRDMO), with operations spanning China, North America, Europe, and other international regions. The company's expertise covers the entire lifecycle, from discovery and research to development and manufacturing, of biopharmaceutical products. WuXi XDC Cayman operates in the Medical - Diagnostics & Research industry within the Healthcare sector.
Paasa handles the paperwork
Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.
Frequently asked questions
Can I buy WuXi XDC Cayman stock from India?
Yes. Indian residents and NRIs can buy WuXi XDC Cayman (2268) shares directly through Paasa. WuXi XDC Cayman is listed on the Hong Kong Stock Exchange, in the Medical - Diagnostics & Research industry. Your money leaves India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name at Interactive Brokers.
Do I need to buy a full WuXi XDC Cayman share?
Usually more than one, and not a fraction: many Hong Kong listings trade in board lots, so the smallest order is one lot rather than one share. At HK$80.80 a share, size the order by the lot, not by the share.
How are WuXi XDC Cayman dividends taxed for Indian investors?
WuXi XDC Cayman trades on the Hong Kong Stock Exchange but is domiciled in China, so any withholding on its dividends follows that country's rules rather than those of Hong Kong. Dividends are taxed at your slab rate in India. Paasa's dividend report shows the gross amount and any tax withheld for each payment.
What tax do I pay in India when I sell WuXi XDC Cayman shares?
Hong Kong generally does not levy capital gains tax on non-resident individual investors for HKEX-listed stocks. In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the HKD/INR rate on the day you bought and the day you sold, so the currency move is part of the gain. Paasa's capital-gains statement gives you the figures for your return.